(Q35621763)

9 August 2017

1 reference

title

Challenges in therapy of chronic hepatitis B. (English)

1 reference

9 August 2017

1 reference

Jay H Hoofnagle

1

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39 Suppl 1

1 reference

9 August 2017

S230-5

1 reference

Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Serum HBV-DNA levels in inactive hepatitis B virus carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900332-5

7 January 2021

10.1016/S0168-8278(03)00332-5

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14708709